Global Macrolide Antibiotics Market – Industry Trends and Forecast to 2031

Macrolide Antibiotics Market Analysis and Size

As per recent data approximately 1 billion cases of the common cold are diagnosed and treated each year in the U.S., it is estimated that there are around 14.5 million outpatient visits each year for skin and soft tissue infections. Also, the incidence rates of sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and syphilis are increasing. It is estimated that approximately 131 million new cases of chlamydia occur worldwide each year. The global incidence of gonorrhea is estimated to be around 87 million new cases per year whereas it is estimated that there are approximately 6 million new cases of syphilis worldwide each year.

Data Bridge Market Research analyzes that the global macrolide antibiotics market which was USD 70,597.06 million in 2023, is likely to reach USD 187,678.33 million by 2031, and is expected to undergo a CAGR of 13.0% during the forecast period. “Azithromycin” dominates the drug segment of the market due to the growing demand for better methods for treatment in patients. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Macrolides refer to a class of antibiotics that are derived from Saccharopolyspora erythraea, and inhibit protein synthesis in bacteria by binding to the 50S ribosomal element. These antibiotics are effective against gram positive bacteria and intracellular pathogens, such as Chlamydia and Mycoplasma and Legionella.

Global Macrolide Antibiotics Market Dynamics

Drivers

• Rising prevalence of bacterial infections

Bacterial infections continue to be a significant health concern globally. The increasing prevalence of respiratory tract infections, skin and soft tissue infections, and other bacterial infections drives the demand for macrolide antibiotics as they are effective in treating a broad range of bacterial pathogens.

• Growing awareness and healthcare infrastructure

Increased awareness about the importance of appropriate antibiotic use and improved healthcare infrastructure play a role in driving the demand for macrolide antibiotics. Access to healthcare facilities, diagnostic capabilities, and availability of antibiotics contribute to increased demand.

Opportunities

• Increasing demand for macrolides in emerging markets

Emerging markets, such as China, India, Brazil, and other developing countries, offer significant growth opportunities for the macrolide antibiotics market. These regions have large populations and increasing healthcare expenditures, which contribute to higher demand for antibiotics. Additionally, the rising prevalence of bacterial infections and the need for effective treatment options in these markets create opportunities for macrolide antibiotics manufacturers to expand their presence and tap into these growing markets.

• Development of novel macrolide antibiotics

Continuous research and development efforts in the field of antibiotics offer opportunities for the development of novel macrolide antibiotics. The emergence of drug-resistant bacteria and the need for new therapeutic options drive the exploration of new macrolide compounds with enhanced efficacy and reduced resistance. Developing macrolides with improved pharmacokinetic profiles, broader spectrum of activity, and reduced side effects can provide a competitive advantage and open up new market opportunities.

Restraints/Challenges

• Antibiotic resistance

The emergence and spread of antibiotic-resistant bacteria pose a significant challenge to the market. Overuse and misuse of antibiotics, including macrolides, contribute to the development of resistance. This can limit the effectiveness of macrolide antibiotics in treating bacterial infections and reduce their long-term market potential. The growing prevalence of antibiotic-resistant bacteria necessitates the development of new antibiotics and alternative treatment strategies to address this challenge.

• Side effects and safety concerns

While macrolide antibiotics are generally well-tolerated, they can still have side effects and safety concerns. Common side effects include gastrointestinal disturbances, such as nausea, vomiting, and diarrhea. There are also rare instances of more serious adverse effects, such as cardiac arrhythmias, liver toxicity, and allergic reactions. These safety concerns can impact patient compliance, limit the use of macrolides in certain patient populations, and potentially lead to regulatory scrutiny. Ensuring the safety and appropriate use of macrolide antibiotics is an ongoing challenge for manufacturers and healthcare providers.

This macrolide antibiotics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the macrolide antibiotics market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.

Recent Development

• In 2019, the Food and Drug Administration (USFDA) approved Fetroja, an innovative antibiotic that targets multi-drug resistant gram-negative bacteria. It offers an alternative treatment option for complicated urinary tract infections

Global Macrolide Antibiotics Market Scope

The macrolide antibiotics market is segmented on the basis of drugs, route of administration, infection and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

• Azithromycin
• Clarithromycin
• Erythromycin
• Fidaxomicin
• Telithromycin

Route of Administration

• Oral
• Parenteral

Infection

• Mycoplasma Pneumoniae
• Legionella Sp.
• Bordetella Pertussis
• Symptomatic Cat-Scratch Disease
• Bacillary Angiomatosis
• Peliosishepatis
• Cerebral Toxoplasmosis
• Uncomplicated Skin Infections

End User

• Hospital
• Dermatology Clinic
• Clinic
• Ambulatory Centre
• Research Laboratories

Global Macrolide Antibiotics Market Regional Analysis/Insights

The macrolide antibiotics market is analyzed and market size insights and trends are provided by country, drugs, route of administration, infection and end user as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and rest of Middle East and Africa.

North America is expected to dominate the market due to the rise in prevalence of bacterial skin infection within the region, strong base of healthcare facilities, the strong presence of major players in the market and the extraordinary healthcare infrastructure.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2024 to 2031 due to the increase growing awareness about the use of macrolides for the treatment of uncomplicated skin infections in the region, increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for diagnosis and treatment procedures, the large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The macrolide antibiotics market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the macrolide antibiotics market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the macrolide antibiotics market.

Competitive Landscape and Global Macrolide Antibiotics Market Share Analysis

The macrolide antibiotics market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the macrolide antibiotics market.

Some of the major players operating in the macrolide antibiotics market are:

• GlaxoSmithKline plc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• Eli Lily and Company (U.S.)
• Pfizer Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Novartis AG (Switzerland)
• Boehringer Ingelheim International Gmbh (Germany)
• Sanofi (France)
• Astrazeneca (U.K.)
• AbbVie Inc. (U.S.)
• Abbott (U.S.)
• Bayer AG (Germany)
• Sandoz International GmbH (Germany)
• Johnson & Johnson Services, Inc. (U.S.)
• Zhejiang Guobang Pharmaceutical Co., Ltd. (China)
• Barkat Pharmaceutical Group (Iran)

SKU-14445